ERBB2 and cancer: This novel ET‐CORM‐antibody conjugate releases carbon monoxide upon cleavage by the tumor‐associated protease cathepsin B. The construct enables selective intracellular CO delivery to HER2‐overexpressing and CatB‐expressing cells, presenting a new strategy for targeted, CO‐based cancer therapies.